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ABSTRACT 
Adrenal tumors are usually diagnosed by clinical symptoms of hor- 
mone excess. The increasing use of ultrasound and computed tomog- 
raphy results in the detection of a substantial number of incidentally 
discovered adrenal tumors. Most of these tumors are nonfunctional 
adrenocortical adenomas, but a few cases of subclinical cortisol pro- 
duction in “incidentalomas” have been reported. We investigated pro- 
spectively the prevalence of autonomous cortisol production in 68 
patients (44 females and 24 males, aged 25-90 yr) with adrenal inci- 
dentalomas at our institution. As a screening procedure all patients 
with incidentalomas underwent an overnight dexamethasone suppres- 
sion test (1 mg). Patients who failed to suppress serum cortisol below 
140 nmol/L (5 pg/dL) underwent more comprehensive studies (pro- 
longed dexamethasone suppression test, determination of the diurnal 
rhythm of cortisol secretion in saliva, and CRH stimulation test). Eight 
patients (12% of all patients with incidentalomas; 5 females and 3 
males, aged 25-71 yr) were finally identified as having cortisol-produc- 
ing tumors, and the findings in these patients were compared with 
those of overt Cushina’s syndrome in 8 uatients (8 females. awd 26-50 
yr) suffering from coriisoi-producing adrenal adenomas. - 
The tumor size of patients with cortisol-producing incidentalomas 
ranged from 2-5 cm. No specific signs and symptoms of hypercortisol- 
ism were present, but arterial hypertension (seven of eight subjects), 
diffuse obesity (four of eight subjects), and noninsulin-dependent dia- 
betes mellitus (NIDDM; two of eight subjects) were frequently ob- 
served. Baseline cortisol levels were in the normal to upper normal 
range, whereas baseline ACTH levels were suppressed in five of the 
eight patients. In none of the patients was serum cortisol suppressible 
by low dose or high dose dexamethasone. The ACTH and cortisol 
responses to CRH were normal in two, blunted in one, and suppressed 
in four patients. Unilateral adrenalectomy was performed in seven 
patients and resulted in temporary adrenal insufficiency in four of 
them. After surgery, improvement of arterial hypertension, a perma- 
nent weight loss in obese subjects, and a better metabolic control of 
NIDDM were noted in the majority of patients. 
The following conclusions were reached. Incidentally diagnosed ad- 
renal tumors with pathological cortisol secretion in otherwise clinically 
asymptomatic patients are more frequently observed than previously 
assumed. Adrenocortical insufficiency is a major risk in these patients 
after adrenalectomy. After surgery, hypertension, obesity, and NIDDM 
may improve. Patients with asymptomatic adrenal incidentalomas, 
therefore, should be screened for cortisol production by means of an 
overnight dexamethasone suppression test. (J Clin Endocrinol Metab 
75: 826-832, 1992) 
F UNCTIONAL adrenocortical tumors are usually associ- ated with signs and symptoms of hormone excess. In 
contrast, nonfunctional tumors are presumed if the patients 
are asymptomatic, and baseline hormone levels are in the 
normal range. With wider application of ultrasound, com- 
puted tomography (CT), and, more recently, magnetic reso- 
nance imaging (MRI), adrenal neoplasms have been detected 
incidentally in increasing frequency (l-l 1). These so-called 
“incidentalomas” of the adrenal gland are usually asympto- 
matic and are often classified as nonfunctional tumors. How- 
ever, these lesions may be truly nonfunctional or may secrete 
adrenocortical hormones in amounts insufficient to cause 
clinically apparent disease. In recent years there have been 
several case reports of functional adrenal nodules secreting 
cortisol without clinical evidence of Cushing’s syndrome (12- 
18). Since the prevalence of autonomous glucocorticoid se- 
cretion by incidentally detected adrenal tumors is unknown, 
the hormonal evaluation of patients with incidentalomas is 
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still controversial. Recently, Ross and Aron (19) concluded 
that the low probability of cortisol production in adrenal 
incidentalomas does not justify endocrine screening proce- 
dures such as the overnight dexamethasone suppression test. 
However, there is growing evidence that cortisol production 
by asymptomatic adrenal tumors is more frequently observed 
than assumed until now. Hensen et al. (20) reported 3 
cortisol-producing tumors (6%) in a series of 50 incidentalo- 
mas. More recently, in a retrospective study, 6 of 122 patients 
(5%) with adrenal incidentalomas were shown to harbor 
cortisol-producing tumors, but the study was hampered by 
incomplete endocrine data (21). In our series of 68 patients 
with asymptomatic adrenal tumors, 8 patients (12%) were 
subsequently found to have pathological cortisol production 
by their tumor. This high prevalence emphasizes the impor- 
tance of a careful endocrinological evaluation in patients 
with adrenal incidentalomas. 
Patients 
Subjects and Methods 
Eighty-two patients with asymptomatic incidentally discovered ad- 
renal tumors were prospectively evaluated at the Medical Department 
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ABSTRACT 
Adrenal tumors are usually diagnosed by clinical symptoms of hor-
mone excess. The increasing use of ultrasound and computed tomog-
raphy results in the detection of a substantial number of incidentally 
discovered adrenal tumors. Most of these tumors are nonfunctional 
adrenocortical adenomas, but a few cases of subclinical cortisol pro-
duction in "incidentalomas" have been reported. We investigated pro-
spectively the prevalence of autonomous cortisol production in 68 
patients (44 females and 24 males, aged 25-90 yr) with adrenal inci-
dentalomas at our institution. As a screening procedure all patients 
with incidentalomas underwent an overnight dexamethasone suppres-
sion test (1 mg). Patients who failed to suppress serum cortisol below 
140 nmol/L (5 j.lg/dL) underwent more comprehensive studies (pro-
longed dexamethasone suppression test, determination of the diurnal 
rhythm of cortisol secretion in saliva, and CRH stimulation test). Eight 
patients (12% of all patients with incidentalomas; 5 females and 3 
males, aged 25-71 yr) were finally identified as having cortisol-produc-
ing tumors, and the findings in these patients were compared with 
those of overt Cushing's syndrome in 8 patients (8 females, aged 26-50 
yr) suffering from cortisol-producing adrenal adenomas. 
The tumor size of patients with cortisol-producing incidentalomas 
ranged from 2-5 cm. No specific signs and symptoms of hypercortisol-
PUNCTIONAL adrenocortical tumors are usuaUy associ-ated with signs and symptoms of hormone excess. In 
contrast, nonfunctional tumors are presumed if the patients 
are asymptomatic, and baseline hormone levels are in the 
normal range. With wider application of ultra sound, com-
pu ted tomography (CT), and, more recently, magnetic reso-
nance imaging (MRI), adrenal neoplasms have been detected 
incidentally in increasing frequency (1-11). These so-called 
"incidentalomas" of the adrenal gland are usually asympto-
matic and are often classified as nonfunctional tumors. How-
ever, these lesions may be truly nonfunctional or may secrete 
adrenocortical hormones in amounts insufficient to cause 
clinically apparent disease. In recent years there have been 
several case reports of functional adrenal nodules secreting 
cortisol without clinical evidence of Cushing's syndrome (12-
18). Since the prevalence of autonomous glucocorticoid se-
cretion by incidentally detected adrenal tumors is unknown, 
the hormonal evaluation of patients with incidentalomas is 
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ism were present, but arterial hypertension (seven of eight subjects), 
diffuse obesity (four of eight subjects), and noninsulin-dependent dia-
betes mellitus (NIDDM; two of eight subjects) were frequently ob-
served. Baseline cortisol levels were in the normal to upper normal 
range, whereas baseline ACTH levels were suppressed in five of the 
eight patients. In none of the patients was serum cortisol suppressible 
by low dose or high dose dexamethasone. The ACTH and cortisol 
responses to CRH were normal in two, blunted in one, and suppressed 
in four patients. Unilateral adrenalectomy was performed in seven 
patients and resulted in temporary adrenal insufficiency in four of 
them. After surgery, improvement of arte rial hypertension, a perma-
nent weight loss in obese subjects, and a better metabolie control of 
NIDDM were noted in the majority of patients. 
The following conclusions were reached. Incidentally diagnosed ad-
renal tumors with pathological cortisol secretion in otherwise clinically 
asymptomatic patients are more frequently observed than previously 
assumed. Adrenocortical insufficiency is a major risk in these patients 
after adrenalectomy. After surgery, hypertension, obesity, and NIDDM 
may improve. Patients with asymptomatic adrenal incidentalomas, 
therefore, should be screened for cortisol production by means of an 
overnight dexamethasone suppression test. (J Clin Endocrinol Metab 
75: 826-832, 1992) 
still controversial. Recently, Ross and Aron (19) concluded 
that the low probability of cortisol production in adrenal 
incidentalomas does not justify endocrine screening proce-
dures such as the overnight dexamethasone suppression test. 
However, there is growing evidence that cortisol production 
by asymptomatic adrenal tumors is more frequently observed 
than assumed until now. Hensen et al. (20) reported 3 
cortisol-producing tumors (6%) in aseries of 50 incidentalo-
mas. More recently, in a retrospective study, 6 of 122 patients 
(5%) with adrenal incidentalomas were shown to harbor 
cortisol-producing tumors, but the study was hampered by 
incomplete endocrine data (21). In our series of 68 patients 
with asymptomatic adrenal tumors, 8 patients (12%) were 
subsequently found to have pathological cortisol production 
by their tumor. This high prevalence emphasizes the impor-
tance of a careful endocrinological evaluation in patients 
with adrenal incidentalomas. 
Sub;ects and Methods 
Patients 
Eighty-two patient  with asymptomatic incidentally discovered ad-
renal tumors were pröspectively evaluated at the Medical Department 
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II of the University of Cologne from 1982-1989. The majority of patients 
were referred from internists in private practice or medical departments 
of other hospitals. The adrenal tumors were discovered by ultrasound 
or CT of the abdomen, invariably performed for the evaluation of an 
unrelated disease. Patients suffering from known malignancies undergo- 
ing staging procedures (n = 10) and patients with questionable enlarge- 
ment of the adrenals (n = 4) were excluded. None of the remaining 68 
patients showed specific signs and symptoms of hormone excess. As a 
screening procedure all patients underwent an overnight, low dose 
dexamethasone suppression test (1 mg dexamethasone at 2300 h and 
determination of serum cortisol at 0900 h on the following day) and 
collected 24-h urine volume for measurement of catecholamines and 
aldosterone excretion. In addition, serum potassium levels were deter- 
mined once. 
and 2, 3 mg at 2300 h; days 3 and 4, 2 mg, four times a day; 
determination of serum cortisol at 0900 h every day). The response of 
the pituitary-adrenal axis to exogenous CRH was assessed using human 
CRH (100 rg Corticobiss, iv, at 0900 h; Bissendorf Peptide, Wedemark, 
Germany). In the control group (patients with adrenal Cushing’s syn- 
drome), lysine vasopressin (5 IU, iv, for 60 min) was used before 1984 
(n = 2). A rise in cortisol concentrations greater than 120 nmol/L (4.7 
pg/dL) was considered a positive response. 
Serum cortisol (Serono, Freiburg, Germany) was measured by a 
commercial enzyme-linked immunosorbent assay. Urinary free cortisol 
excretion was determined by RIA (NEN, Dreieich, Germany). Salivary 
cortisol was measured by RIA, as previously described (22). Plasma 
ACTH was determined by RIA after extraction with QUSO G32 (23). 
The lower limit of detection was 1 pmol/L. 
Patients who failed to suppress serum cortisol to below 140 nmol/L 
(5 Fg/dL) after administration of 1 mg dexamethasone underwent more 
comprehensive biochemical testing of adrenal function (see below). The 
criteria used to make the diagnosis of autonomous cortisol production 
by the tumor (preclinical Cushing’s syndrome) were as follows: 1) the 
patient had no overt clinical signs of Cushing’s syndrome (arterial 
hypertension (>160/95 mm Hg), obesity (>120% of ideal weight), and 
noninsulin dependent diabetes mellitus (NIDDM) were not considered 
to be specific symptoms because they are frequently found in patients 
with adrenal incidentalomas); 2) the patient had no complaints directly 
attributable to the disease; 3) the adrenal mass was detected incidentally; 
4) serum cortisol levels were repeatedly not suppressible below 90 nmol/ 
L (3 rg/dL) by low dose and high dose dexamethasone; and 5) the 
failure to suppress cortisol by dexamethasone was restored to normal 
by adrenalectomy, or adrenalectomy resulted in adrenal insufficiency 
(one patient who was ineligible for surgery did not meet this criterion). 
Radiological studies 
CT scans were performed as 4- or 8-mm thick continuous slices with 
a Somatotom 2, Somatotom DR, or Somatotom DRH scanner (Siemens, 
Erlangen, Germany) before and after iv administration of contrast ma- 
terial. 
Five patients with preclinical Cushing’s syndrome underwent MRI of 
the adrenal glands using the fast field-echo pulse sequence technique at 
1.5 T (Gyroscan S 15, Philips Medical Systems, Best, The Netherlands) 
before and after the administration of 0.1 mmol/kg gadolinium diethy- 
lenetriaminepentaacetic acid (Gd-DTPA, Schering, Berlin, Germany) 
(24). 
Pathology 
Eight of 68 patients (12%) with adrenal incidentalomas were shown 
to have autonomous cortisol production by the tumor. In addition, 1 
pheochromocytoma and 1 aldosteronoma were found in this series (data 
not shown). 
Eight patients suffering from Cushing’s syndrome due to unilateral 
adrenocortical adenomas served as a control group. These patients were 
treated at our institution between 1977 and 1988 and were studied 
retrospectively. The clinical data of all patients presented in this report 
are shown in Table 1. 
All surgically removed asymptomatic tumors and five of eight symp- 
tomatic cortisol-producing tumors were available for histopathological 
studies. Light microscopy was performed using routine staining methods 
of paraffin-embedded sections, including immunostaining for neuron- 
specific enolase and Dll as a specific marker for adrenocortical tissue 
(25). 
Statistical analysis 
Endocrine assessment 
The results are expressed as the mean + 1 SD. Statistical analysis was 
performed by two-tailed Wilcoxon test for unpaired data. Significance 
was retained for P < 0.05. 
Adrenocortical function was assessed using routine endocrine tech- 
niques. The following tests were performed: baseline serum cortisol and 
ACTH were measured at 0900 h, the diurnal variation in cortisol 
secretion was determined by measuring salivary cortisol in l-h intervals 
between 0900-2300 h (22), 24-h urine volume was collected for meas- 
urement of urinary free cortisol excretion (n = 4); and pituitary-adrenal 
suppressibility was tested by administration of dexamethasone (days 1 
Clinical data 
Results 
Patients with preclinical Cushing’s syndrome were 
younger than patients with nonfunctional adrenal inciden- 
TABLE 1. Clinical data of patients with nonfunctional incidentalomas, cortisol-producing incidentalomas (preclinical Cushing’s syndrome), 
and symptomatic cortisol-producing adrenal adenomas causing overt Cushing’s syndrome 
Patients with incidentalomas 
Nonfunctional Preclinical Cushing’s syndrome 
Overt Gushing’s 
syndrome 
No. 
Age (yd 
Sex (%) 
Male 
Female 
Tumor size (by CT; cm) 
Tumor location (% ) 
Left adrenal 
Right adrenal 
Bilateral 
Temporary adrenal insufficiency after 
adrenalectomy [no. (%)] 
Duration of glucococorticoid replace- 
ment therapy (months) 
58 8 8 
59 + 12 (25-90) 50 + 15 (25-71) 39 + 8 (26-50) 
36 37 0 
64 63 100 
3.0 + 2.0 (1.0-15.0) 3.7 + 1.0 (2.0-5.0) 3.9 t 0.9 (2.0-4.5) 
44 37 50 
35 63 50 
417 (57) 8/8 (100) 
17 + 15 (S-39; 4)” 19 + 8 (9-33; 8) 
a Range; number of subjects. 
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patients showed specific signs and symptoms of hormone excess. s a 
screening procedure all patients underwent an overnight, low dose 
dexamethasone suppression test (1 g dexamethasone at 2300 hand 
determination of serum cortisol at 0900 h on the following day) and 
collected 24-h urine volume for measurement of catecholamines and 
aldosterone excretion. In addition, serum potassium levels were deter-
mined once. 
Patients who failed to suppress serum cortisol to below 140 nmol/L 
(5 J,tg/dL) after administration of 1 mg dexamethasone underwent more 
comprehensive biochemical testing of adrenal function (see below). The 
criteria used to make the dia gnosis of autonomous cortisol production 
by the tumor (precJinical Cushing's syndrome) were as folIows: 1) the 
patient had no overt cIinical signs of Cushing's syndrome (arterial 
hypertension (>160/95 mm Hg), obesity (>120% of ideal weight), and 
noninsulin dependent diabetes mellitus (NIDOM) were not considered 
to be specific symptoms because they are frequently found in patients 
with adrenal incidentalomas); 2) the patient had no complaint5 directly 
attributable to the disease; 3) the adrenal mass was detected incidentally; 
4) serum cortisollevels were repeatedly not suppressible below 90 nmol/ 
L (3 J,tg/dL) by low dose and high dose dexamethasone; and 5) the 
failure to suppress cortisol by dexamethasone was restored to normal 
by adrenalectomy, or adrenalectomy resulted in adrenal insufficiency 
(one patient who was ineligible for surgery did not meet this criterion). 
Eight of 68 patients (12%) with adrenal incidentalomas were shown 
to have autonomous cortisol production by the tumor. In addition, 1 
pheochromocytoma and 1 aldosteron oma were found in this series (data 
not shown). 
Eight patients suffering from Cushing's syndrome due to unilateral 
adrenocortical adenomas served as a control group. These patients were 
treated at our institution between 1977 and 1988 and were studied 
retrospectively. The cIinical da ta of all patients presented in this report 
are shown in Table 1. 
Endocrine assessment 
Adrenocortical function was assessed using routine endocrine tech-
niques. The following tests were performed: baseline serum cortisol and 
ACTB were measured at 0900 h, the diurnal variation in cortisol 
secretion was determined by measuring salivary cortisol in I-h intervals 
between 0900-2300 h (22), 24-h urine volume was collected for meas-
urement of urinary free cortisol excretion (n 4); and pituitary-adrenal 
suppressibility was tested by administration of dexamethasone (days 1 
d ,  g t 0 ; ays  d ,  , ur ti es  y; 
termination f s rum rtisol t 0  ery ay). he r sponse f 
t e ituit ry- drenal is t  ogenous B as se sed ing man 
B (100 J,tg orticobiss, iv, at 0900 h; issendorf eptide, edemark, 
ermany). In the control group (patients ith adrenal ushing's syn-
drome), lysine vasopressin (5 IU, iv, for 60 in) as used before 1984 
(n = 2).  rise in cortisol concentrations greater than 120 n ol/L (4.7 
J,tg/dL) was considered a positive response. 
Serum cortisol (Serono, Freiburg, Germany) was easured by a 
commercial enzyme-linked immunosorbent assay. Urinary free cortisol 
excretion was determined by RIA (NEN, Oreieich, Germany). Salivary 
cortisol was easured by RIA, as previously described (22). Plasma 
ACTH was determined by RIA after extraction with QUSO G32 (23). 
The lower limit of detection was 1 pmol/L. 
Radiological studies 
CT scans were performed as 4- or 8-mm thick continuous sliees with 
a Somatotom 2, Somatotom OR, or Somatotom ORB scanner (Siemens, 
Erlangen, Germany) be fore and after iv administration of contrast ma-
terial. 
Five patients with prec\inical Cushing's syndrome underwent MRI of 
the adrenal glands using the fast fjeld-echo pulse sequence technique at 
1.5 T (Gyrosean S 15, Philips Medical Systems, Best, The Netheriands) 
before and after the administration of 0.1 mmol/kg gadolinium diethy-
lenetriaminepentaacetic acid (Gd-OTPA, Schering, Berlin, Germany) 
(24). 
Pathology 
All surgically removed asymptomatic tumors and five of eight symp-
tomatie cortisol-producing tumors were available for histopathological 
studies. Light microscopy was performed using routine staining methods 
of paraffin-embedded seetions, incIuding immunostaining for neuron-
specific enolase and Oll as a specific marker for adrenocortical tissue 
(25). 
Statistical analysis 
The results are expressed as the mean ± 1 so. Statistical analysis was 
performed by two-tailed Wi\coxon test for unpaired data. Significance 
was retained for P < 0.05. 
Results 
Clinical data 
Patients with preclinical Cushing's syndrome were 
younger than patients with nonfunctional adrenal inciden-
TABLE 1. Clinical data of patients with nonfunctional incidentalomas, cortisol-producing incidentalomas (preclinical Cushing's syndrome), 
and symptomatic cortisol-producing adrenal adenomas causing overt Cushing's syndrome 
No. 
Age (yr) 
Sex (%) 
Mal  
Female 
Tumor size (by CT; em) 
Tumor lo ation (%) 
Left adre l 
Right adrenal 
Bil teral 
Tempor ry adrenal insufficiency after 
adrenalectomy (n . (%)] 
Ouration of glucococorticoid replace-
ment therapy (months) 
" Range; number of subjects. 
Patients with incidentalomas 
Nonfunctional 
58 
59 ± 12 (25-90) 
36 
64 
3.0 ± 2.0 (1.0-15.0) 
44 
35 
21 
0/8 (0) 
PrecJinical Cushing's 
syndrome 
8 
50 ± 15 (25-71) 
37 
63 
3.7 ± 1.0 (2.0-5.0) 
37 
63 
4/7 (57) 
17 ± 15 (8-39; 4)" 
Overt Cushing's 
syndrome 
8 
39 ± 8 (26-50) 
o 
10  
3.9 ± 0.9 (2.0-4.5) 
 
50 
8/8 (100) 
19 ± 8 (9-33; 8) 
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talomas but older than patients with overt adrenal Cushing’s 
syndrome (Table 1). Female patients were more frequently 
observed in all three groups. Mean tumor size, determined 
by CT, was smaller in nonfunctional tumors than in both 
preclinical Cushing’s syndrome and overt Cushing’s syn- 
drome. Tumor location caused no significant difference. 
Specific signs and symptoms of Cushing’s syndrome were 
absent in patients with nonfunctional adrenal incidentalomas 
(Table 2). In preclinical Cushing’s syndrome, the majority of 
patients lacked classical Cushing’s signs. One patient had a 
mild moon-face appearance, which, however, could only be 
identified retrospectively when this feature disappeared after 
adrenalectomy. Hypertension, diffuse obesity, and NIDDM 
were frequently observed in all patients with adrenal neo- 
plasm. 
Endocrine data 
The endocrine results of the individuals with preclinical 
Cushing’s syndrome are shown in Table 3. Biochemically, 
the patients exhibited different stages of hypercortisolism. 
Patient 1, for example, had an abnormal dexamethasone 
suppression test, but normal urinary free cortisol excretion, 
normal diurnal rhythm of salivary free cortisol, and a normal 
response to CRH. In contrast, patients 6-8 showed biochem- 
ical characteristics of adrenal Cushing’s syndrome, with lost 
diurnal rhythm of cortisol secretion, elevated urinary free 
cortisol excretion, nonsuppressible cortisol by dexametha- 
sone, and no response of ACTH to CRH. Apparently, the 
degree of hypercortisolism in preclinical Cushing’s syndrome 
ranged from slightly abnormal to completely pathological 
and was indistinguishable from that in overt adrenal Cush- 
ing’s syndrome in some of the patients. One may, therefore, 
speculate whether this spectrum represents the natural 
course of cortisol-producing tumors evolving toward symp- 
tomatic Cushing’s syndrome. 
Mean hormone values in patients with preclinical Cush- 
ing’s syndrome and patients with overt adrenal Cushing’s 
TABLE 2. Signs and symptoms of Cushing’s syndrome in patients 
with nonfunctional incidentalomas (n = 58), patients with cortisol- 
producing incidentalomas (preclinical Cushing’s syndrome; n = S), 
and patients with overt adrenal Cushing’s syndrome (n = 8) 
Patients with incidentalomas overt cushings 
Nonfunctional Cortisol-producing syndrome 
Moon-face 0 12.5" 100 
Central obesity 0 0 87.5 
Hirsutism 5 12.5 87.5 
Buffalo hump 0 0 62.5 
Striae rubrae 0 0 62.5 
Ekchymosis 0 0 62.5 
Oligo-amenorhoe 0 0 62.5 
Psychiatric symptoms 0 0 50 
Osteoporosis 0 0 37.5 
Edema 11 0 25 
Arterial hypertension 46 75 62.5 
Diffuse obesity 36 50 12.5 
NIDDM 21 25 12.5 
Values given are percentages. 
‘Was detected retrospectively after adrenalectomy. 
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TABLE 4. Endocrine data (mean f SD, range) of patients with preclinical Cushing’s syndrome and overt Cushing’s syndrome 
Preclinical Cushing’s Overt Cushing’s 
syndrome syndrome Normal range 
Baseline serum cortisol at 0900 h 
(nmol/L) 
Baseline ACTH at 0900 h (pmol/L) 
Serum cortisol after 1 mg dexametha- 
sone (nmol/L) 
Serum cortisol after 3 mg dexametha- 
sone (nmol/L) 
Serum cortisol after 4 x 2 mg dexa- 
methasone (nmol/L) 
Cortisol increase in response to CRH/ 
LVP (>120 nmol/L) 
417 + 176 (176-756) 533 + 142 (459-719) 140-680 
1.4 +- 0.7 (<LO-2.9) 1.1 -+ 0.3 (l-1.7) 3.7 + 2.2 
464 f 204 (204-815) 514 + 260 (88-830) <140 
330f 175 (100-670) 435 + 197 (193-691) <140 
398 k 175 (100-735) 503 + 196(207-719) <90 
317 O/7 
The observed differences were not statistically significant. To convert ACTH concentrations to picograms per mL, multiply by 4.5; to convert 
cortisol concentrations to micrograms per dL, multiply with 0.04. LVP, lysine vasopressin. Values are the mean + SD; the range is in parentheses. 
syndrome are shown in Table 4. Although not significantly 
different, we observed a tendency for ACTH levels to be 
higher and cortisol values to be lower in preclinical Cushing’s 
syndrome compared to overt adrenal Cushing’s syndrome. 
The diurnal rhythm of salivary free cortisol was lost in all 
patients with overt adrenal Cushing’s syndrome and in six 
patients with preclinical Cushing’s syndrome (Fig. 1). One 
patient with preclinical Cushing’s syndrome had a normal 
diurnal rhythm of cortisol secretion. 
The administration of low and high dose dexamethasone 
did not suppress serum cortisol concentrations in preclinical 
Cushing’s syndrome as well as in overt Cushing’s syndrome 
(Fig. 2). This demonstrates the autonomous nature of cortisol 
secretion by these tumors. 
The mean response of ACTH to stimulation with CRH 
was suppressed in overt adrenal Cushing’s syndrome, but 
blunted in preclinical Cushing’s syndrome. In addition, mean 
serum cortisol concentrations after stimulation were slightly 
elevated in preclinical Cushing’s syndrome, but not in overt 
Cushing’s syndrome. 
The preoperative CRH test was useful in identifying pa- 
tients with preclinical Cushing’s syndrome at risk for second- 
ary adrenal insufficiency after adrenalectomy. In patients 
who showed a serum cortisol increase of at least 120 nmol/ 
L in response to CRH, adrenocortical function remained 
1 I 
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A. lime lhourl B. Itme I hours b 
FIG. 1. Salivary cortisol concentrations between 0700-2300 h in pa- 
tients with preclinical Cushing’s syndrome (A) and patients with overt 
Cushing’s syndrome (B). The shaded area represents the normal range. 
intact after removal of the tumor. All patients in whom 
serum cortisol was unresponsive to CRH suffered from ad- 
renal insufficiency. 
Radiological studies (preclinical Gushing’s syndrome) 
On CT images, all patients with preclinical Cushing’s 
syndrome had lesions less than 6 cm in diameter, sharp 
margins, and a round shape. On plain scans, MRI showed 
low signal intensities on Tl-weighted scans and relative 
signal intensities under 2.0 on T2-weighted images. The 
dynamic contrast-enhanced studies showed a moderate en- 
hancement and quick wash-out in four tumors. In only one 
highly vasculated adenoma was enhancement stronger and 
wash-out slower, indicative of a malignant adrenal tumor. 
Histology 
Seven of eight patients with preclinical Cushing’s syn- 
drome underwent unilateral adrenalectomy. One patient suf- 
fered from advanced atherosclerosis and was ineligible for 
surgery. He died 5 months later due to an unrelated disease. 
An autopsy was not performed. 
In all cases compact cell or spongiocytic adrenocortical 
adenomas were found. Ipsilateral atrophy of the adjacent 
adrenal cortex was noted in four patients and correlated well 
with suppressed baseline ACTH levels in these patients 
(Table 3). The morphology of tumors in preclinical Cushing’s 
syndrome was similar to that in overt Cushing’s syndrome. 
No significant differences were found in tumor size, tissue 
pattern, quantity of spongiocytic cells, adipose tissue, and 
myolipomatous foci. Upon neuron-specific enolase staining, 
some of the tumors in both groups showed sparse reactivity. 
Dll immunocytochemistry, a selective marker of adrenocor- 
tical tissue, exhibited clear reactivity of various degrees in all 
tumors. 
Postoperative course 
After adrenalectomy, four of the patients with preclinical 
Cushing’s syndrome suffered from secondary adrenal insuf- 
ficiency requiring replacement therapy. Baseline cortisol con- 
centrations at 0900 h were below 140 nmol/L (5 pg/dL) in 
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Serum cortisol after 3 g dexametha-
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Serum cortisol after 4 x 2 mg dexa-
methasone (nmol/L) 
Cortisol increase in response to CRH/ 
L VP (>120 nmol/L) 
reclinical shing's 
ndrome 
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398 ± 175 (100-735) 
/  
vert shing's ormal ge drome 
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The observed differences were not statistically significant. To convert ACTH concentrations to picograms per mL, multiply by 4.5; to convert 
cortisol concentrations to micrograms per dL, multiply with 0.04. LVP, lysine vasopressin. Values are the mean ± SD; the range ia in parentheses. 
syndrome are shown in Table 4. Although not significantly 
different, we observed a tendency for ACTH levels to be 
higher and cortisol va lues to be lower in preclinical Cushing' s 
syndrome compared to overt adrenal Cushing's syndrome. 
The diurnal rhythm of salivary free cortisol was lost in aH 
patients with overt adrenal Cushing's syndrome and in six 
patients with preclinical Cushing's syndrome (Fig. 1). One 
patient with preclinical Cushing's syndrome had anormal 
diurnal rhythm of cortisol secretion. 
The administration of low and high dose dexamethasone 
did not suppress serum cortisol concentrations in preclinical 
Cushing's syndrome as weH as in overt Cushing's syndrome 
(Fig. 2). This demonstrates the autonomous nature of cortisol 
secretion by these tumors. 
The mean response of ACTH to stimulation with CRH 
was suppressed in overt adrenal Cushing's syndrome, but 
blunted in preclinical Cushing's syndrome. In addition, mean 
serum cortisol concentrations after stimulation were slightly 
elevated in preclinical Cushing's syndrome, but not in overt 
Cushing's syndrome. 
The preoperative CRH test was useful in identifying pa-
tients with preclinical Cushing's syndrome at risk for second-
ary adrenal insuffieiency after adrenalectomy. In patients 
who showed aserum cortisol increase of at least 120 nmol/ 
L in response to CRH, adrenocortical function remained 
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FIG. 1. Salivary cortisol concentrations betwee 0700-2300  in pa-
tients with preclinical Cus ing's syndrome (A) and patie ts with overt 
Cushing's syndrome (B). The shaded area represents the normal range. 
intact after removal of the tumor. All patients in whom 
serum cortisol was unresponsive to CRH suffered from ad-
renal insufficiency. 
Radiological studies (preclinical Cushing's syndrome) 
On CT images, all patients with preclinical Cushing's 
syndrome had lesions less than 6 cm in diameter, sharp 
margins, and a round shape. On plain scans, MRI showed 
low signal intensities on Tl-weighted scans and relative 
signal intensities under 2.0 on T2-weighted images. The 
dynamic contrast-enhanced studies showed a moderate en-
hancement and quick wash-out in four tumors. In only one 
highly vasculated adenoma was enhancement stronger and 
wash-out slower, indicative of a malignant adrenal tumor. 
Histology 
Seven of eight patients with preclinical Cushing's syn-
drome underwent unilateral adrenalectomy. One patient suf-
fered from advanced atherosclerosis and was ineligible for 
surgery. He died 5 months later due to an unrelated disease. 
An autopsy was not performed. 
In all cases compact cell or spongiocytic adrenocortical 
adenomas were found. Ipsilateral atrophy of the adjacent 
adrenal cortex was no ted in four patients and correlated well 
with suppressed baseline ACTH levels in these patients 
(Table 3). The morphology of tumors in preclinical Cushing's 
syndrome was similar to that in overt Cushing's syndrome. 
No significant differences were found in tumor size, tissue 
pattern, quantity of spongiocytic cells, adipose tissue, and 
myolipomatous foei. Upon neuron-speeific enolase staining, 
some of the tumors in both groups showed sparse reactivity . 
D11 immunocytochemistry, a selective marker of adrenocor-
tical tissue, exhibited clear reactivity of various degrees in all 
tumors. 
Postoperative course 
After adrenalectomy, four of the patients with preclinical 
Cushing's syndrome suffered from secondary adrenal insuf-
fieiency requiring replacement therapy. Baseline cortisol con-
centrations at 0900 h were below 140 nmol/L (5 ~g/dL) in 
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FIG. 2. Serum cortisol levels at baseline and during dexamethasone suppression. A, Patients with preclinical Cushing’s syndrome. B, Patients 
with overt Cushing’s syndrome. The shaded bars show the normal range. To convert cortisol concentrations to micrograms per dL, multiply by 
0.04. 
all of these patients, and did not increase above 360 nmol/L 
(13 pg/dL) after stimulation with ACTH-(1-24). The patients 
received glucocorticoid replacement therapy for 8-39 
months. Glucocorticoid therapy could not be withdrawn 
earlier in asymptomatic patients than in patients with overt 
Cushing’s syndrome, of whom all suffered from adrenal 
insufficiency after surgery (Table 1). 
In the remaining three patients with preclinical Cushing’s 
syndrome who had normal adrenocortical function after 
adrenalectomy, serum cortisol was fully suppressible by low 
dose dexamethasone treatment, demonstrating that the lack 
of suppression preoperatively was due to autonomous corti- 
sol production. 
The frequency and severity of arterial hypertension, obe- 
sity, and diabetes mellitus changed considerably in patients 
with preclinical Cushing’s syndrome after adrenalectomy 
(follow-up, 18-60 months; mean, 28 months). 
The four obese patients reported a permanent weight loss 
of more than 5 kg (range up to 20 kg). Three of the hyper- 
tensive patients could reduce the antihypertensive medica- 
tion, and one patient had normal blood pressure levels after 
adrenalectomy. Both patients with diabetes mellitus had 
improvement of glycemic control and could be switched to 
dietary treatment. 
The postoperative course of patients with preclinical Cush- 
ing’s syndrome shows that cortisol production by these tu- 
mors is not completely asymptomatic. Although these tumors 
did not secrete glucocorticoids in amounts sufficient to cause 
overt Cushing’s syndrome, the cortisol excess to some extent 
caused hypertension, obesity, and diabetes mellitus. 
Discussion 
With wider application of ultrasound, CT, and MRI, inci- 
dental adrenal tumors have been detected with increasing 
frequency (l-11). It is estimated that in approximately 0.6- 
2% of all abdominal CTs clinically nonsuspected adrenal 
tumors are discovered (19). The majority of these tumors 
have been shown to represent stable or slowly growing 
adrenocortical adrenal adenomas, whereas metastases from 
occult malignancies, adrenomyelolipomas, pheochromocy- 
tomas, and adrenocortical carcinomas are rarely found. As 
far as endocrine studies have been undertaken, most of the 
lesions have been shown to be nonfunctional. However, 
some of the patients had asymptomatic pheochromocytomas 
(3, 4, 10) or asymptomatic aldosterone-producing tumors 
(25). In addition, there have been several reports of inciden- 
tally detected cortisol-secreting adrenal tumors in otherwise 
healthy subjects (12-19). This entity, therefore, has been 
termed pre-Cushing’s syndrome, subclinical Cushing’s syn- 
drome, or preclinical Cushing’s syndrome. We report here 
the clinical, biochemical, and radiological data of 8 patients 
with this syndrome, who represent 12% of our series of 68 
prospectively studied patients with an incidentally discov- 
ered adrenal mass. 
The prevalence of cortisol-producing tumors has been 
unexpectedly high in our series, accounting for 12% of all 
adrenal incidentalomas. This may be explained by the fact 
that careful endocrine studies are frequently not undertaken 
in these patients. However, recently there have been two 
reports on preclinical Cushing’s syndrome in adrenal inci- 
dentalomas (20, 25). Hensen et al. (20) found cortisol-pro- 
ducing adenomas in 6% of all incidentally detected adrenal 
tumors, whereas McLeod et al. (21) reported a 5% prevalence 
cortisol-producing tumors in 122 patients with incidentalo- 
mas. Seemingly, cortisol production by adrenal tumors is 
more frequently found than assumed until now when thor- 
ough endocrine procedures are undertaken in these patients. 
Autonomous glucocorticoid secretion without signs and 
symptoms of Cushing’s syndrome seems to have some anal- 
ogy to the more commonly recognized thyroid nodule. In the 
latter instance, a thyroid adenoma autonomously secretes 
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a11 of these patients, and did not increase above 360 nmol/L 
(13 ~g/dL) after stimulation with ACTH-(1-24). The patients 
received glucocorticoid replacement therapy for 8-39 
months. Glucocorticoid therapy could not be withdrawn 
earlier in asymptomatic patients than in patients with overt 
Cushing's syndrome, of whom all suffered from adrenal 
insufficiency after surgery (Table 1). 
In the remaining three patients with preclinical Cushing's 
syndrome who had normal adrenocortical function after 
adrenalectomy, serum cortisol was fully suppressible by low 
dose dexamethasone treatment, demonstrating that the lack 
of suppression preoperatively was due to autonomous corti-
sol production. 
The frequency and severity of arterial hypertension, obe-
sity, and diabetes mellitus changed considerably in patients 
with preclinical Cushing's syndrome after adrenalectomy 
(follow-up, 18-60 months; mean, 28 months). 
The four obese patients reported a permanent weight loss 
of more than 5 kg (range up to 20 kg). Three of the hyper-
tensive patients could reduce the antihypertensive medica-
tion, and one patient had normal blood pressure levels after 
adrenalectomy. Both patients with diabetes mellitus had 
improvement of glycemic control and could be switched to 
dietary treatment. 
The postoperative course of patients with preclinical Cush-
ing's syndrome shows that cortisol production by these tu-
mors is not completely asymptomatic. Although these tumors 
did not secrete glucocorticoids in amounts sufficient to cause 
overt Cushing's syndrome, the cortisol excess to some extent 
caused hypertension, obesity, and diabetes mellitus. 
Discussion 
With wider application of ultrasound, CT, and MRI, inci-
dental adrenal tumors have been detected with increasing 
frequency (1-11). It is estimated that in approximately 0.6-
2% of all abdominal CTs clinically nonsuspected adrenal 
tumors are discovered (19). The majority of these tumors 
have been shown to represent stable or slowly growing 
adrenocortical adrenal adenomas, whereas metastases from 
occult malignancies, adrenomyelolipomas, pheochromocy-
tomas, and adrenocortical carcinomas are rarely found. As 
far as endocrine studies have been undertaken, most of the 
lesions have been shown to be nonfunctional. However, 
some of the patients had asymptomatic pheochromocytomas 
(3, 4, 10) or asymptomatic aldosterone-producing tumors 
(25). In addition, there have been several reports of inciden-
tally detected cortisol-secreting adrenal tumors in otherwise 
healthy subjects (12-19). This entity, therefore, has been 
termed pre-Cushing's syndrome, subclinical Cushing's syn-
drome, or preclinical Cushing's syndrome. We report here 
the clinical, biochemical, and radiological da ta of 8 patients 
with this syndrome, who represent 12% of our series of 68 
prospectively studied patients with an incidentally discov-
ered adrenal mass. 
The prevalence of cortisol-producing tumors has been 
unexpectedly high in our series, accounting for 12% of a11 
adrenal incidentalomas. This may be explained by the fact 
that careful endocrine studies are frequently not undertaken 
in these patients. However, recently there have been two 
re ports on preclinical Cushing's syndrome in adrenal inci-
dentalomas (20, 25). Hensen et al. (20) found cortisol-pro-
ducing adenomas in 6% of a11 incidentally detected adrenal 
tumors, whereas McLeod ef al. (21) reported a 5% prevalence 
cortisol-producing tumors in 122 patients with incidentalo-
mas. Seemingly, cortisol production by adrenal tumors is 
more frequently found than assumed until now when thor-
ough endocrine procedures are undertaken in these patients. 
Autonomous glucocorticoid secretion without signs and 
symptoms of Cushing's syndrome seems to have some anal-
ogy to the more commonly recognized thyroid nodule. In the 
latter instance, a thyroid adenoma autonomously secretes 
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thyroid hormones. The surrounding normal thyroid gland 
may be incompletely (warm nodule) or completely (hot nod- 
ule) suppressed. Hyperthyroidism, however, develops in 
only 20% of patients. This outcome is more likely when the 
adenoma exceeds 3 cm in diameter. The clinical course of 
autonomous cortisol-secreting tumors in patients with pre- 
clinical Cushing’s syndrome is not known. However, tumor 
size seems to be of minor importance in this entity. Compar- 
ison of the tumor size in our series showed that the mean 
diameter did not differ in preclinical Cushing’s syndrome 
and overt Cushing’s syndrome. 
Comparison of the biochemical features of preclinical 
Cushing’s syndrome with those of overt Cushing’s syndrome 
showed clear differences in the clinical and biochemical 
characteristics of these entities, although the observed differ- 
ences were not statistically significant due to the limited 
number of patients. However, the hypercortisolism tended 
to be of lesser degree in preclinical Cushing’s syndrome 
compared to overt Cushing’s syndrome. Baseline cortisol 
levels were slightly lower in these patients, and plasma 
ACTH levels were higher than those in patients with overt 
Cushing’s syndrome. In none of the patients with Cushing’s 
syndrome did ACTH and cortisol levels respond to stimula- 
tion with CRH or lysine vasopressin, whereas three of seven 
patients with preclinical Cushing’s syndrome showed a rise 
in ACTH and cortisol levels. Complete suppression of the 
pituitary-adrenal axis, resulting in adrenocortical insuffi- 
ciency after adrenalectomy, was evident in all patients with 
overt Cushing’s syndrome, but in only four of seven patients 
with preclinical Cushing’s syndrome. These data support the 
concept that cortisol-producing tumors in adrenal inciden- 
talomas secrete glucocorticoids in amounts insufficient to 
cause overt Cushing’s syndrome. 
As a group, the endocrine findings in patients with pre- 
clinical Cushing’s syndrome were heterogenous. This may 
be explained by variable amounts and variable duration of 
cortisol secretion by such tumors. Cortisol secretion by the 
tumor probably initially results in blunting of the diurnal 
variation and a lack of suppression of cortisol by dexameth- 
asone. As ACTH is suppressed to low levels, the CRH test 
becomes progressively abnormal. Finally, excretion of uri- 
nary cortisol exceeds the normal range. 
Our results show that the best screening test for preclinical 
Cushing’s syndrome in patients with an incidentally discov- 
ered mass is the low dose dexamethasone test, which was 
abnormal in all of our patients. These results are in agreement 
with the reported cases in the literature, which all showed 
an abnormal response to dexamethasone (14, 16-18,20,21). 
In contrast, urinary cortisol excretion was normal in three of 
four of our patients tested. Six of nine patients previously 
reported also showed normal 24-h urinary cortisol levels. 
Therefore, urinary cortisol is not a sensitive indicator of 
hypercortisolism in these patients. Determination of diurnal 
cortisol secretion is also of limited value in the evaluation of 
these patients. It is not a practical out-patient test, and the 
results may be difficult to interpret if the cortisol production 
rate is low and evening cortisol levels are only slightly 
elevated. 
Should patients with preclinical Cushing’s syndrome 
undergo adrenalectomy? At the moment this question re- 
mains to be answered. Charbonnel et al. (14) reported a 
patient with an asymptomatic cortisol-producing tumor who 
initially refused surgery. The patient remained in good health 
for 5 yr, at which time he finally agreed to undergo adrenal- 
ectomy. This case demonstrates that the natural course of 
asymptomatic cortisol-producing adenomas can be stable. 
Apparently, preclinical Cushing’s syndrome may not neces- 
sarily evolve toward overt Cushing’s syndrome. However, 
Hensen et al. (26) reported a similar patient in whom after 1 
yr a mild form of overt Cushing’s syndrome (striae and 
buffalo hump) developed (26). This case shows that preclin- 
ical Cushing’s syndrome can progress to Cushing’s syn- 
drome. Therefore, it mey be argued that adrenalectomy is 
generally required in these patients to avoid morbidity from 
Cushing’s syndrome. The hypothetical concept of tumorigen- 
esis of cortisol-producing tumors is summarized in Fig. 3. 
Additional reasons for surgery may be seen in the improve- 
ment of arterial hypertension, obesity, and diabetes mellitus 
that was observed in our patients after adrenalectomy. Al- 
though the tumors did not secrete glucocorticoids in amounts 
sufficient to cause overt Cushing’s syndrome, the cortisol 
excess was not completely asymptomatic and apparently 
resulted to some extent in hypertension, weight gain, and 
diabetes mellitus. In patients with accelerated arterial hyper- 
tension and obesity, therefore, we recommend adrenalec- 
tomy as the treatment of choice. Completely asymptomatic 
FIG. 3. Hypothetical model of the tumorigenesis of cortisol-producing 
tumors. 
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patients and very old patients may be treated conservatively, 
but close follow-up studies are then indicated. 
In summary, we report the series of eight patients with 
asymptomatic cortisol-producing adrenal adenomas. These 
tumors represent 12% of a series of 68 patients with inciden- 
tally discovered adrenal tumors. Because the natural course 
of preclinical Cushing’s syndrome is not known yet, we 
recommend adrenalectomy as the treatment of choice only 
in young patients and patients with arterial hypertension, 
weight gain, or newly recognized diabetes mellitus. In addi- 
tion, adrenalectomy should be performed if tumor size (~6 
cm) and contrast-enhanced MR images rise the suspicion of 
an adrenocortical carcinoma. 
Acknowledgments 
We thank Mrs. M. Breuer, Mrs. N. Hofmann, Mrs. G. Rossbach, and 
Mrs. D. Vollmer for skillful technical assistance. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
References 
Geelhoed GW, Drury EM. 1982 Management of the adrenal “in- 
cidentaloma.” Surgery. 92866-9. 
Glazer HS, Weyman PJ, Sage1 SS, Levitt RG, McClennan BL. 
1982 Nonfunctioning adrenal masses. Am J Radiol. 139:81-5. 
Prinz AM, Brooks MH, Churchill H, et al. 1982 incidental asymp- 
tomatic adrenal masses detected by computed tomography scan- 
ning. JAMA. 248:701-4. 
Copeland PM. 1983 The incidentally discovered adrenal mass. Ann 
Intern Med. 98:940-5. 
Mitnick JS, Bosniak MS, Megibow AJ, Naidich DP. 1983 Non- 
functioning adrenal adenomas discovered incidentally on computed 
tomography. Radiology. 148:495-9. 
Garz G, Luning M, Melzer 8. 1985 Computertomographische 
Zufallsbefunde von hormoninaktiven Nebennierenrindenadeno- 
men. Radio1 Diagn (Berlin). 26:761-6. 
Guerrero LA. 1985 Diagnostic and therapeutic approach to inciden- 
tal adrenal mass. Urology. 26:435-8. - _. 
Seddon TM. Baranetskv N. van Boxel PI. 1985 Adrenal “inciden- 
talomas.’ Urology. 25:1-7. 
Belldegrun A, Hussain S, Seltzer E, Loughlin KR, Gittes RF, 
Richie JP. 1986 Incidentally discovered mass of the adrenal gland. 
Surg Gynecol Obstet. 163:203-7. 
Waldner H, Wilker D, Eibl-Eibesfeld 8. 1986 Therapeutisches 
Vorgehen beim ‘lncidentalom” der Nebenniere. Chirurg. 57:557-9. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22 
23. 
24 
25 
26 
Reincke M, Winkelmann W, Jaursch-Hancke C, et al. 1989 Diag- 
nostik und Therapie asymptomatischer Nebennierentumoren. Dtsch 
Med Wochenschr. 114:861-5. 
Beierwaltes WH, Sturman MF, Ryo U. 1974 Imaging functional 
nodules of the adrenal glands with ‘3’l-19-iodocholesterol. J Nucl 
Med. 15:246-51. 
Rizza RA, Wahner HW, Spelsberg TC. 1978 Visualization of 
nonfunctioning adrenal adenomas with iodocholesterol: possible 
relationshiu to subcellular distribution of tracer. I Nucl Med. 19:458- 
63. ’ 
Charbonnel B, Chatal JF, Ozanne P. 1981 Does the corticoadrenal 
adenoma with “pre-Cushing’s” syndrome exist? J Nucl Med. 
22:1059-61. 
Bertagna C, Orth DN. 1981 Clinical and laboratory findings and 
results of therapy in 58 patients with adrenocortical tumors admitted 
to a single medical center (1951-1978). Am J Med. 71:855-75. 
Banner V, Eggens U, Hensen 1, et al. 1986 lncidentallv discovered 
AC%H-depet%ent adrenal adenoma presenting as “pie-Cushing’s 
syndrome.” Acta Endocrinol (Copenh). 111:89-92. 
Beyer HS, Doe RP. 1986 Cortisol secretion by an incidentally 
discovered nonfunctional adrenal adenoma. J Clin Endocrinol Me- 
tab. 62:1317-21. 
Huiras CM, Pehling GB, Caplan RH. 1989 Adrenal insufficiency 
after operative removal of apparently nonfunctioning adrenal ade- 
nomas. JAMA. 261:894-8. 
Ross N, Aron D. 1990 Hormonal evaluation of the patient with an 
incidentally discovered adrenal mass, N Engl J Med. 323:1401-5. 
Hensen J, Buhl M, Oelkers W. 1990 Diagnostisches und therapeu- 
tisches Vorgehen bei Patienten mit zufaellig entdeckten Nebenni- 
erentumoren. In: Allolio B, Schulte HM, eds. Moderne Diagnostik 
und therapeutische Strategien bei Nebennierenerkrankungen. New 
York: Schattauer Verlag Stuttgart; pp 210-5. 
McLeod M, Thomuson N, Gross M, Bondeson A, Bondeson L. 
1990 Sub-clinical Gushing’s syndrome in patients with adrenal 
gland incidentalomas. Pitfalls in diagnosis and management. Am 
Surgeon. 56:398-403. 
Allolio 8, Feltes G, De@ U, Kaulen D, Winkelmann W. 1985 
Direkter Radioimmunoassay von freiem Cortisol im Speichel. Lab 
Med. 9:281-4. 
Allolio B, Winkelmann W, Hipp FX. 1981 Effect of meclastine, an 
Hl-antihistamine, on plasma ACTH in adrenal insufficiency. Acta 
Endocrinol (Copenh). 97:98-102. 
Krestin GP, Steinbrich W, Friedmann G. 1989 Adrenal masses: 
evaluation with fast gradient-echo MR imaging and Gd-DTPA- 
enhanced dynamic studies. Radiology. 171:67?-80. 
Schroder S. Niendorf A, Achilles E. et al. 1990 Immunocvtochem- 
ical differential diagnosis of adrenal.neoplasms using the monoclo- 
nal antibody Dll. Virchows Arch [Pathol Anat]. 417:89-96. 
Hensen J, Buhl M, Bahr V, Oelkers W. 1990 Endocrine activity of 
the “silent” adrenocortical adenoma is uncovered by response to 
corticotropin-releasing hormone. Klin Wochenschr. 68:608-14. 
 at UBM Klinikum Innenstadt on October 30, 2008 jcem.endojournals.orgDownloaded from 
832 INCKE  L. E ·19 2 
o175·No3 
y   ely, 
 d  low-up  cate  
  t ri s   th 
is l-producing s.  
t   series   th de
ly l se    
 di  i '    n , 
l      
  t th  , 
t  ly  l t  i
 r e    >  
ras -e ha  s  spici   
r  . 
cknowledgments 
e hank rs. . reuer, rs. . ofmann, rs. . o sbach, d 
rs. . ollmer or illful chnical istance. 
ef rences 
elhoed , rury . 82 anag ment f e renal "in-
identaloma." rgery. 2:866-9. 
 lazer S, eyman , agel , evitt G, cClennan . 
82 onfunctioning drenal a ses. m adiol. 9:81-5. 
 rinz M, r oks H, hurchill ,  . 82 Incidental ymp-
matic drenal a ses etected y omputed omography an-
ing. MA. 48:701-4. 
. opeland . 983 he cidentally iscovered renal a s. n 
ntern ed. 8:940-5. 
 itnick , osniak S, egibow J, aidich OP. 83 on-
unctioning renal enomas iscovered ncidentally n mputed 
tomography. adi logy. 48:4 5-9. 
 arz , u ing , elzer B. 85 omputertomographische 
ufallsbefunde on ormoninaktiven ebenniere rindenadeno-
en. adiol iagn erlin). 6:761-6. 
. ue rero . 85 iagnostic d erapeutic proach  nciden-
l renal a s. r logy. 6:435-8. 
. e don J , aranetsky , an oxel J. 85 drenal "inciden-
talomas." r logy. :1-7. 
. elldegrun , ussain eltzer , oughlin R, ittes F, 
ichie . 86 ncidentally iscovered a s f e renal land. 
urg ynecol bstet. 63:203-7. 
. aldner , ilker 0, ibl-Eibesfeld B. 86 herapeuti ches 
org hen eim "Incidentalom" r ebenniere. hi urg. 7: 57-9. 
. eincke , inkelmann , }aursch-Hancke , t . 89 iag-
ostik nd herapie mptomatischer ebennierentumoren. tsch 
ed ochenschr. 4:861-5. 
. eierwaltes H, turman F, yo . 74 aging nctional 
odules f he renal lands ith t 1I-19-iodoch lesterol. ucI 
ed. 5:246-51. 
. izza , ahn er , eisberg . 78 isualization  
onfunctioning renal enomas ith docholesterol: ssible 
elationship  bcellular istribution  acer. J ucI ed. :458-
. 
. harbonnel , h tal , zanne  81 oes e rticoadrenal 
enoma ith "pre-Cushing's' ndrome ist? ucI ed. 
: 1059-61. 
. ertagna , rth ON. 81 Iinical d boratory indings d 
sults f herapy   atients ith ren cortical ors itted 
 ngle edical enter 95 -1978).  ed. :855-75. 
. ogner , ggens , ensen J, t . 86 I cidentally iscovered 
CTH-dependent renal enoma ese ting  "pre-Cushing's 
ndrome." cta ndocrinol openh).  :8 -92. 
. eyer S, Ooe . 986 rtisol retion y  cidentally 
iscovered onfunctional renal enoma. lin docrinol e-
t . :1317-21. 
. uiras , hling , aplan . 89 drenal i sufficiency 
ter erative emoval f parently onfunctioning renal e-
mas. MA. 1:894-8. 
. o s , ron O. 90 ormonal aluation f e atient ith  
cidentally iscovered renal a s.  gl ed. 3:1401-5. 
. ensen , uhl , elkers . 90 iagnostisches d t erapeu-
tisches org hen ei tienten it faellig tdeckten ebenni-
rentumoren. n: llolio , hulte , s. oderne iagnostik 
nd erapeutische trategien i ebenni enerkrankungen. ew 
ork: chattauer erlag tuttgart; p 0-5. 
. cLeod , hompson , ross , ondeson , ondeson  
90 b-cIinical Cushing's s ndrome i  tients ith renal 
land i cidentalomas. itfalls i  iagnosis d anag ment. m 
rgeon. 6:398-403. 
. l lio B, eltes , Oeuß , aulen 0, inkel mann . 85 
irekter ad oimmunoassay on reiem ortisol  eichel. ab 
ed. 281-4. 
. ll lio , inkelmann , i p . 81 ffect f eclastine, a  
l-antihistamine, n lasma CTH i  renal i sufficiency. cta 
ndocrinol openh). :98-102. 
. restin P, teinbrich , riedmann . 89 drenal a ses: 
aluation ith ast radient-echo R aging d d-DTP A-
e hanced namic studies. adi logy. 1:675-80. 
. chroder , iendorf , chilles , t l. 90 I muno ytochem-
i al i f rential iagnosis f renal neoplasms ing t e nocIo-
l tibody l1. irchows rch athol nat]. 7:8 -96. 
. ensen J, uhl , ahr , elkers . 90 docrine activity f 
t e "silent" ren cortical enoma i  covered  response t  
rtic tropin-releasing rmone. lin ochenschr. :608-14. 
